Circa Life Sciences Tackles the Rapid Growth of the Medical Cannabis Industry in Colombia and How it’s changing the Methodology of Treating Patients

The approval of GW Pharmaceutical’s Epidiolex, an oral solution derived from cannabidiol (CBD), brought about a positive impact in the Colombia market and became a key indicator that cannabis can be used medically.

It has been recommended to treat two difficult types of epilepsy which are Lennox-Gastaut and Dravet syndrome even though there are other medications available. In a clinical trial, 32% of the patients who received 10-milligram doses experienced at least 37% reduction in seizures which established the high probability of the cannabis effectiveness in epilepsy.

Another company who ventured in the promising use of medical cannabis is Zynerba Pharmaceuticals. They have been developing a permeation-enhanced gel or ZYN002 to help in treating Developmental and Epileptic Encephalopathies (DEE), Adult Refractory Focal Epilepsy and Fragile X syndrome.

The land down under didn’t get left behind with Creso Pharma leading the way. Originally, Creso is established to showcase the medical wonders of cannabis. No wonder it has been the first to import medical cannabis in Australia. In addition, it has also launched innovative products into Switzerland such as anibidiol and cannaQIX.

Just last Tuesday, Creso Pharma has announced that Kunna S.A.S. is officially granted with a license to cultivate medical cannabis Colombia. It would be remembered that Creso is due to acquire Kunna S.A.S. later this month. Once the acquisition is finalized, CPH will have the ability to supply the Colombia market with planned products and do export at the same time.
Aside from pharmaceutical companies, we have seen advancement in import and distribution business entities wherein one of which is Aphria Inc (Aphria). The Canadian medical cannabis company had recently announced its exclusive supply agreement with Colcanna SAS (Colcanna).

In an interview, Vic Neufeld (CEO of Aphria) said, “We see tremendous potential for medical cannabis in several emerging markets, including Colombia. We are thrilled to enter the Colombian-market through this exclusive agreement with Colcanna. Aphria will continue to expand its global leadership through strategic investments, partnerships, and agreements such as this one.”

Colombia has been known to be one of the pioneer countries who naturally embraced the use of medical cannabis. With the boom of the medical cannabis industry, there is a higher possibility that production and distribution can be higher. Further clinical trials will also be developed. But, as it progresses, we can expect its implementation can also be stricter.

Visit us at http://circalifesciences.com/

It has been recommended to treat two difficult types of epilepsy which are Lennox-Gastaut and Dravet syndrome even though there are other medications available.

181 Fort York Blvd., Toronto, ON

This release was published on openPR.